Grants Search Results

This grant supports a Clinical Research Associate to ensure that more Adolescent and Young Adults can be treated on clinical trials, often their best hope for a cure.

This grant supports a dedicated Adolescent and Young Adult (AYA) cancer survivorship program at Ochsner, to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a nurse educator for the Adolescent and Young Adult (AYA) program at this institution to improve patient outcomes and care.

This grant funds research personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports an adolescent-young Adult (AYA) liaison to ensure that more AYAs can be treated on clinical trials, often their best hope for a cure.

Genetic studies have identified the molecular causes of childhood cancers such as T-cell leukemia and neuroblastoma. A recurrent theme in these cancers is abnormal activation of the MYC gene. Accordingly, researchers like Dr. Wendel have spent much time and effort in trying to identify inhibitors of MYC as they believe these could be very powerful therapies for these childhood cancers. Dr. Wendel and his colleagues recently found a new way to block the production of MYC using a natural compound. The natural product is rare and hard to come by and therefore Dr. Wendel and his colleagues are exploring ways to generate synthetic drugs based on this plant product. With support from the St. Baldrick’s Foundation they are working to bring this new strategy to the clinic. They focus especially on heavily pre-treated and relapsed childhood leukemia because affected children have few options and they hope to make a difference.

Neuroblastoma is a cancer of the cells that become nerve tissues in the body, except in the brain. Dr. Bernstein is studying the effect of a particular mutation in neuroblastoma – an event that alters the DNA sequence to promote cancer. This mutation lies in a gene called ATRX. Dr. Bernstein takes a genomics approach to understand how ATRX mutations promote neuroblastoma in order to discover new therapies for children with ATRX mutations.

Based on progress to date, Dr. Brinkman was awarded a new grant in 2018 to fund an additional year of this Scholar grant. Survivors of childhood brain tumors are at-risk for problems with developing social relationships. These problems can lead to feelings of isolation, loneliness and social anxiety. Dr. Brinkman believes this is due to changes in a survivor's brain due to their cancer and its treatment. Dr. Brinkman's research aims to examine how the structure and function of the brain is related to survivors' understanding of social information and their social behavior. These results aim to help with the identification of treatments for social problems.

This new award is generously supported by the Team Campbell Foundation, established in memory of Campbell Hoyt, who courageously battled anaplastic ependymoma, a rare cancer of the brain and spine for five years. Its mission is to improve the lives of families facing a childhood cancer diagnosis through raising awareness, funding research and providing psycho-social enrichment opportunities.

Although germ cell tumors are the most common solid tumors of adolescents and young adults, care and progress has been hampered by fragmentation between pediatric and adult oncology. No major breakthrough in therapy has occurred for over three decades. Limited genetic understanding hampers researchers' ability to tailor therapy or discover new drugs that could change outcomes. This international consortium of the world's leading scientists and clinicians from both pediatric and medical oncology aim to make significant advances in clinical trial design and genomic understanding of germ cell tumors.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.